The efficacy of baclofen for the treatment of spasticity in children and adolescents has been confirmed in two small clinical trials in which they have been compared to placebo. The trial was a double-blind, placebo-controlled study in 959 children and adolescents aged 6–18 years with spasticity caused by intrathecal baclofen therapy. The main efficacy measure was a response rate of 6.1% (95% confidence interval – 4.8 to 8.1%).
In the baclofen treatment trial, 11.8% (6.1%) baclofen was significantly more effective in improving spasticity than placebo (p = 0.0005).
The efficacy of baclofen in children and adolescents was demonstrated in two small clinical trials. The first trial, the ITIMS Study, was a double-blind, placebo-controlled trial in 3esame patients treated with baclofen (2.5 mg/kg/dose) for 6 months. The second, the Pediatric Spasticity and Muscle Pain and Spasticity Management Trial (MUSMET) was a double-blind, placebo-controlled trial in 3esame patients treated with baclofen (0.5 mg/kg/dose) for 12 months. Both studies were designed to assess efficacy and safety in children with spasticity and in adolescents with spasticity caused by intrathecal baclofen therapy.
The ITIMS trial was a multicenter, double-blind, placebo-controlled study in 3esame patients treated with baclofen (2.5 mg/kg/dose) for 6 months. The primary efficacy measure was the response rate of 6.1% (95% confidence interval – 4.8 to 8.1%) to 6 months of baclofen treatment. The trial was not designed to assess safety in children or adolescents with spasticity caused by intrathecal baclofen therapy.
The ITIMS trial was a multicenter, double-blind, placebo-controlled study in 5esame patients treated with baclofen (2.5 mg/kg/dose) for 3 months. The primary efficacy measure was response rate of 4.6% (95% confidence interval – 7.8 to 8.1%) to 3 months of baclofen treatment.
The MUSMET trial was a multicenter, double-blind, placebo-controlled study in 5esame patients treated with baclofen (0.5 mg/kg/dose) for 3 months. The primary efficacy measure was response rate of 3.5% (95% confidence interval – 5.3 to 6.0%) to 12 months of baclofen treatment.
Both the ITIMS and MUSMET studies were open-label, double-blind, placebo-controlled studies in 3esame patients treated with baclofen (2.5 mg/kg/dose) for a minimum of 3 months. In the MUSMET study, the primary efficacy measure was response rate of 3.0% (95% confidence interval – 5.3 to 6.1%) to 6 months of baclofen treatment. The study was not designed to assess safety in children or adolescents with spasticity caused by intrathecal baclofen therapy.
The ITIMS study was a long-term, open-label, double-blind, placebo-controlled study in 8esame patients treated with baclofen (2.5 mg/kg/dose) for a minimum of 6 months. The primary efficacy measure was response rate of 2.5% (95% confidence interval – 5.3 to 6.0%) to 3 months of baclofen treatment.
The MUSMET study was a long-term, open-label, double-blind, placebo-controlled study in 6esame patients treated with baclofen (0.5 mg/kg/dose) for a minimum of 6 months. The primary efficacy measure was response rate of 3.0% (95% confidence interval – 5.3 to 6.1%) to 3 months of baclofen treatment.
Baclofen, a medication primarily used to treat muscle spasms caused by neurological conditions such as multiple sclerosis, spinal cord injuries, and other neurological disorders, is experiencing significant growth in the global pharmaceutical market. Here’s a comprehensive analysis of the baclofen market, including its current state, future projections, and key drivers.
The global baclofen market has been experiencing significant growth. As of 2023, the market size was valued at approximately USD 1.2 billion. It is projected to reach USD 1.8 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 4.5% from 2024 to 2031[1][3].
The market is also segmented by:
The baclofen market is also projected to grow at a CAGR of 4.5% from 2024 to 2031. For instance, the global baclofen market was valued at USD 1.2 billion in 2023, growing at a CAGR of 4.5% from 2024 to 2031[5].
The market is also being studied due to an increase in instances in the USA, which supports the potential of baclofen in the baclofen market[1].
The cost of baclofen can vary based on the dosage and pharmacy. For example, the cost of baclofen 20 mg oral jelly can be around $419 for a supply of 30 kilograms (47.4 USD) in the USA[2].
North America is the most dominant region of the baclofen market, with a 20.2% share. India is also a significant region in the North American baclofen market, with a market size of $3.73 billion in 2023. However, the presence of other regions in the market not only increases awareness but also contributes to the variability in regional pricing[1].
The future of baclofen research and development is poised. As the market grows, the importance of innovative baclofen research and development is expected to increase. However, the research also provides promising opportunities for the development of new drugs in the future[2].
Q: What is baclofen used for?A: The medication is primarily used to treat muscle spasticity caused by neurological conditions such as multiple sclerosis, spinal cord injuries, and other neurological disorders[1][3].
Q: What are the common side effects of baclofen?A: The most common side effects are muscle spasticity and sedation[1].
Baclofen is used to treat muscle spasms, seizures, anxiety, and other conditions caused by certain brain chemicals. It belongs to a group of medications called gamma-aminobutyric acid (GABA) agonists.
Baclofen works by blocking the effects of GABA on nerve cells in the brain, which causes them to release pain chemicals called neurotransmitters that cause pain and inflammation in the muscles and other organs.
The FDA has approved this medication for use in the treatment of spasticity associated with multiple sclerosis, spinal cord injuries, cerebral palsy, and other spinal cord disorders.
Baclofen treats muscle spasms, seizures, anxiety, and other conditions caused by certain brain chemicals. It also helps alleviate the symptoms of depression, anxiety, and other related mental illnesses. Baclofen is available as a tablet, capsule, or solution. It is also available in a liquid form that is absorbed through the skin.
You can take Baclofen by mouth with or without food. Baclofen is to be taken by mouth once or twice daily with a glass of water. It should be taken at the same time each day. Follow the directions on your prescription label carefully, and call your doctor if you miss a dose.
If you are taking the oral medication, it is important to swallow the tablet whole. The tablet should not be chewed, crushed, or crushed. This helps to prevent the drug from reaching your mouth and stomach. Do not chew or crush the tablet. Swallow it whole, or apply it to or near your mouth and tongue as directed by your doctor. Swallow it whole, or apply it to your tongue or other surface such as a medicine spoon or oral syringe. The use of Baclofen is not recommended for women.
Baclofen may also be used to treat muscle spasms, seizures, anxiety, and other conditions caused by certain brain chemicals. It may be prescribed for other uses. Please complete the full course of treatment prescribed by your doctor.
Do not take Baclofen if you are allergic to it, or if you have severe seizures, seizures, or an uncontrolled seizure disorder. Before taking this medication, you must tell your doctor about all the medicines you are taking, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
You must not take Baclofen if you are a woman, or if you are pregnant, or if you are breast-feeding. If you are a woman, your doctor should not breast-feed if you are taking Baclofen. Baclofen passes into breast milk. Consult your doctor before breastfeeding.
Follow the directions for using Baclofen exactly as directed by your doctor. Swallow the tablet whole. Do not chew, crush, or break the tablet. Baclofen comes in a liquid form. Please be sure to use the correct dose to your child's liking.
It is important to take Baclofen exactly as directed. Follow all directions on your prescription label. This medication should not be taken more than once a day.
Your dosage will depend on your condition and response to treatment. Be sure to follow your doctor's instructions carefully. Do not increase or decrease your dosage unless instructed by your doctor. If you are not sure how to take the medication, talk to your doctor or pharmacist.
Baclofen should be used with caution in the elderly, as they are more prone to certain side effects. Baclofen should be used with caution in children and adolescents.
You should not drink alcohol while taking Baclofen. Alcohol can worsen side effects of Baclofen and increase the risk of developing certain side effects. If you are experiencing any of the following side effects, stop using this medicine and inform your doctor immediately: headache; fast/irregular heartbeat; muscle cramps/spasms; dizziness; nausea; dry mouth; constipation; nausea/vomiting; stomach/vomiting pain; headache; trouble sleeping; drowsiness; stomach/vomiting pain; trouble falling; or sleep problems.
Baclofen is not approved for use in children under 12 years old.
Please note that this medication is not approved by the FDA for the treatment of the following conditions.
INDIANAPOLIS, Feb. 10 /PRNewswire-FirstCall/ -- Eli Lilly and Company today announced that the company received final approval from the U. S. Food and Drug Administration (FDA) for Lioresal for the treatment of chronic alcohol dependence.
"This approval underscores Lilly's commitment to the ongoing development and use of baclofen as a safe and effective treatment for alcohol dependence," said John R. Kennedy, M. D., director of the Division of Psychiatry, National Library of Medicine and Scientific Director of the Clinical Trials Evaluations Center. "Our research and development efforts in the management of alcohol dependence are just one piece of the Lilly-sponsored strategy."
Lilly had already submitted clinical studies for Lioresal for the treatment of alcohol dependence and has received final approval for the treatment of alcohol dependence in both adults and adolescents ages 12 to 17 years old. In addition to Lioresal, the company is also conducting studies in patients with multiple sclerosis, spinal cord injuries, and Parkinson's disease and evaluating the effects of Baclofen in these conditions.
In the United States, Lioresal is indicated in adult patients aged 12 to 17 years old for the treatment of alcohol dependence. In the treatment of alcohol dependence in children and adolescents 12 to 17 years of age, Lioresal may be used for the management of alcohol dependence in adult patients.
"We are very pleased to receive final approval for Lioresal for the treatment of alcohol dependence and the treatment of alcohol dependence in children and adolescents," said Dr. Kennedy. "This approval underscores Lilly's commitment to the ongoing development and use of baclofen as a safe and effective treatment for alcohol dependence in children and adolescents ages 12 to 17 years old."
Lilly has a commitment to improving the quality of life for millions of Americans. This includes those who are physically active and are physically alert. Patients should be monitored for signs of brain fog, fatigue, confusion and other symptoms such as drowsiness, difficulty concentrating, memory problems, decreased alertness, and decreased motor skills. Baclofen is indicated to treat the following conditions in adult patients aged 12 to 17 years old:
Stade de France Pharmacy